 | • レポートコード：D005-09121 • 出版社/出版日：GlobalInfoResearch / 2020年5月22日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、151ページ • 納品方法：Eメール • 産業分類：医療・製薬 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、腎臓がん治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。腎臓がん治療薬の種類別市場規模（血管新生阻害剤、mTOR阻害剤、モノクローナル抗体、サイトカイン免疫療法（IL-2））、用途別市場規模（腎細胞がん（RCC）、移行上皮がん（TCC））、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Bayer、Amgen、Novartis、Roche、Active Biotech、GlaxoSmithKline、ArQule、Abbott Laboratories、Pfizer、Argos Therapeutics、Exelixis、Immunicum、AVEO Pharmaceuticals、Onyx Therapeutics、Genentech、Cerulean Pharma、Bionomics、Ono Pharmaceutical、immatics biotechnologies、Bristol-Myers Squibb、Oxford BioMedica、Wilex、Tracon Pharmaceuticals、Taiwan Liposome、Prometheus Laboratories、Seattle Genetics ・地域別グローバル市場分析 2015年-2020年 ・腎臓がん治療薬の北米市場（アメリカ、カナダ、メキシコ） ・腎臓がん治療薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・腎臓がん治療薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・腎臓がん治療薬の南米市場（ブラジル、アルゼンチン） ・腎臓がん治療薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：血管新生阻害剤、mTOR阻害剤、モノクローナル抗体、サイトカイン免疫療法（IL-2） ・用途別分析：腎細胞がん（RCC）、移行上皮がん（TCC） ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Kidney Cancer Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.1% in the forecast period of 2020 to 2025 and will expected to reach USD 4731.4 million by 2025, from USD 4023.6 million in 2019.
The Kidney Cancer Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Kidney Cancer Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Kidney Cancer Drugs market has been segmented into
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)
By Application, Kidney Cancer Drugs has been segmented into:
Renal cell carcinoma (RCC)
Transitional cell carcinoma (TCC)
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Kidney Cancer Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Kidney Cancer Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Kidney Cancer Drugs market.
The report offers in-depth assessment of the growth and other aspects of the Kidney Cancer Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Kidney Cancer Drugs Market Share Analysis
Kidney Cancer Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Kidney Cancer Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Kidney Cancer Drugs sales, revenue and market share for each player covered in this report.
The major players covered in Kidney Cancer Drugs are:
Bayer
Amgen
Novartis
Roche
Active Biotech
GlaxoSmithKline
ArQule
Abbott Laboratories
Pfizer
Argos Therapeutics
Exelixis
Immunicum
AVEO Pharmaceuticals
Onyx Therapeutics
Genentech
Cerulean Pharma
Bionomics
Ono Pharmaceutical
immatics biotechnologies
Bristol-Myers Squibb
Oxford BioMedica
Wilex
Tracon Pharmaceuticals
Taiwan Liposome
Prometheus Laboratories
Seattle Genetics
Among other players domestic and global, Kidney Cancer Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Kidney Cancer Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Kidney Cancer Drugs, with price, sales, revenue and global market share of Kidney Cancer Drugs in 2018 and 2019.
Chapter 3, the Kidney Cancer Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Kidney Cancer Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Kidney Cancer Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Kidney Cancer Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Kidney Cancer Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Kidney Cancer Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Angiogenesis Inhibitors
1.2.3 mTOR Inhibitors
1.2.4 Monoclonal Antibodies
1.2.5 Cytokine Immunotherapy (IL-2)
1.3 Market Analysis by Application
1.3.1 Overview: Global Kidney Cancer Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Renal cell carcinoma (RCC)
1.3.3 Transitional cell carcinoma (TCC)
1.4 Overview of Global Kidney Cancer Drugs Market
1.4.1 Global Kidney Cancer Drugs Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Bayer SWOT Analysis
2.1.4 Bayer Product and Services
2.1.5 Bayer Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Amgen SWOT Analysis
2.2.4 Amgen Product and Services
2.2.5 Amgen Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Novartis SWOT Analysis
2.3.4 Novartis Product and Services
2.3.5 Novartis Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Roche SWOT Analysis
2.4.4 Roche Product and Services
2.4.5 Roche Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Active Biotech
2.5.1 Active Biotech Details
2.5.2 Active Biotech Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Active Biotech SWOT Analysis
2.5.4 Active Biotech Product and Services
2.5.5 Active Biotech Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 GlaxoSmithKline
2.6.1 GlaxoSmithKline Details
2.6.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 GlaxoSmithKline SWOT Analysis
2.6.4 GlaxoSmithKline Product and Services
2.6.5 GlaxoSmithKline Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 ArQule
2.7.1 ArQule Details
2.7.2 ArQule Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 ArQule SWOT Analysis
2.7.4 ArQule Product and Services
2.7.5 ArQule Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Abbott Laboratories
2.8.1 Abbott Laboratories Details
2.8.2 Abbott Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Abbott Laboratories SWOT Analysis
2.8.4 Abbott Laboratories Product and Services
2.8.5 Abbott Laboratories Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Pfizer SWOT Analysis
2.9.4 Pfizer Product and Services
2.9.5 Pfizer Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Argos Therapeutics
2.10.1 Argos Therapeutics Details
2.10.2 Argos Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Argos Therapeutics SWOT Analysis
2.10.4 Argos Therapeutics Product and Services
2.10.5 Argos Therapeutics Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Exelixis
2.11.1 Exelixis Details
2.11.2 Exelixis Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Exelixis SWOT Analysis
2.11.4 Exelixis Product and Services
2.11.5 Exelixis Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 Immunicum
2.12.1 Immunicum Details
2.12.2 Immunicum Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Immunicum SWOT Analysis
2.12.4 Immunicum Product and Services
2.12.5 Immunicum Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.13 AVEO Pharmaceuticals
2.13.1 AVEO Pharmaceuticals Details
2.13.2 AVEO Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 AVEO Pharmaceuticals SWOT Analysis
2.13.4 AVEO Pharmaceuticals Product and Services
2.13.5 AVEO Pharmaceuticals Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.14 Onyx Therapeutics
2.14.1 Onyx Therapeutics Details
2.14.2 Onyx Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Onyx Therapeutics SWOT Analysis
2.14.4 Onyx Therapeutics Product and Services
2.14.5 Onyx Therapeutics Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.15 Genentech
2.15.1 Genentech Details
2.15.2 Genentech Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Genentech SWOT Analysis
2.15.4 Genentech Product and Services
2.15.5 Genentech Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.16 Cerulean Pharma
2.16.1 Cerulean Pharma Details
2.16.2 Cerulean Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Cerulean Pharma SWOT Analysis
2.16.4 Cerulean Pharma Product and Services
2.16.5 Cerulean Pharma Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.17 Bionomics
2.17.1 Bionomics Details
2.17.2 Bionomics Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Bionomics SWOT Analysis
2.17.4 Bionomics Product and Services
2.17.5 Bionomics Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.18 Ono Pharmaceutical
2.18.1 Ono Pharmaceutical Details
2.18.2 Ono Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Ono Pharmaceutical SWOT Analysis
2.18.4 Ono Pharmaceutical Product and Services
2.18.5 Ono Pharmaceutical Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.19 immatics biotechnologies
2.19.1 immatics biotechnologies Details
2.19.2 immatics biotechnologies Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 immatics biotechnologies SWOT Analysis
2.19.4 immatics biotechnologies Product and Services
2.19.5 immatics biotechnologies Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.20 Bristol-Myers Squibb
2.20.1 Bristol-Myers Squibb Details
2.20.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.20.3 Bristol-Myers Squibb SWOT Analysis
2.20.4 Bristol-Myers Squibb Product and Services
2.20.5 Bristol-Myers Squibb Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.21 Oxford BioMedica
2.21.1 Oxford BioMedica Details
2.21.2 Oxford BioMedica Major Business and Total Revenue (Financial Highlights) Analysis
2.21.3 Oxford BioMedica SWOT Analysis
2.21.4 Oxford BioMedica Product and Services
2.21.5 Oxford BioMedica Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.22 Wilex
2.22.1 Wilex Details
2.22.2 Wilex Major Business and Total Revenue (Financial Highlights) Analysis
2.22.3 Wilex SWOT Analysis
2.22.4 Wilex Product and Services
2.22.5 Wilex Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.23 Tracon Pharmaceuticals
2.23.1 Tracon Pharmaceuticals Details
2.23.2 Tracon Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.23.3 Tracon Pharmaceuticals SWOT Analysis
2.23.4 Tracon Pharmaceuticals Product and Services
2.23.5 Tracon Pharmaceuticals Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.24 Taiwan Liposome
2.24.1 Taiwan Liposome Details
2.24.2 Taiwan Liposome Major Business and Total Revenue (Financial Highlights) Analysis
2.24.3 Taiwan Liposome SWOT Analysis
2.24.4 Taiwan Liposome Product and Services
2.24.5 Taiwan Liposome Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.25 Prometheus Laboratories
2.25.1 Prometheus Laboratories Details
2.25.2 Prometheus Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
2.25.3 Prometheus Laboratories SWOT Analysis
2.25.4 Prometheus Laboratories Product and Services
2.25.5 Prometheus Laboratories Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.26 Seattle Genetics
2.26.1 Seattle Genetics Details
2.26.2 Seattle Genetics Major Business and Total Revenue (Financial Highlights) Analysis
2.26.3 Seattle Genetics SWOT Analysis
2.26.4 Seattle Genetics Product and Services
2.26.5 Seattle Genetics Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Kidney Cancer Drugs Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Kidney Cancer Drugs Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Kidney Cancer Drugs Manufacturer Market Share in 2019
3.3.2 Top 6 Kidney Cancer Drugs Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Kidney Cancer Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Kidney Cancer Drugs Sales and Market Share by Regions (2015-2020)
4.1.2 Global Kidney Cancer Drugs Revenue and Market Share by Regions (2015-2020)
4.2 North America Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
4.3 Europe Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
4.5 South America Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Kidney Cancer Drugs Sales, Revenue and Market Share by Country
5.1.1 North America Kidney Cancer Drugs Sales and Market Share by Country (2015-2020)
5.1.2 North America Kidney Cancer Drugs Revenue and Market Share by Country (2015-2020)
5.2 United States Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
5.3 Canada Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
5.4 Mexico Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Kidney Cancer Drugs Sales, Revenue and Market Share by Country
6.1.1 Europe Kidney Cancer Drugs Sales and Market Share by Country (2015-2020)
6.1.2 Europe Kidney Cancer Drugs Revenue and Market Share by Country (2015-2020)
6.2 Germany Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
6.3 UK Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
6.4 France Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
6.5 Russia Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
6.6 Italy Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Kidney Cancer Drugs Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Kidney Cancer Drugs Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Kidney Cancer Drugs Revenue and Market Share by Regions (2015-2020)
7.2 China Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
7.3 Japan Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
7.4 Korea Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
7.5 India Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
7.7 Australia Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Kidney Cancer Drugs Sales, Revenue and Market Share by Country
8.1.1 South America Kidney Cancer Drugs Sales and Market Share by Country (2015-2020)
8.1.2 South America Kidney Cancer Drugs Revenue and Market Share by Country (2015-2020)
8.2 Brazil Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
8.3 Argentina Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Kidney Cancer Drugs Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Kidney Cancer Drugs Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Kidney Cancer Drugs Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
9.3 Turkey Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
9.4 Egypt Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
9.5 South Africa Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Kidney Cancer Drugs Sales and Market Share by Type (2015-2020)
10.2 Global Kidney Cancer Drugs Revenue and Market Share by Type (2015-2020)
10.3 Global Kidney Cancer Drugs Price by Type (2015-2020)
11 Global Kidney Cancer Drugs Market Segment by Application
11.1 Global Kidney Cancer Drugs Sales Market Share by Application (2015-2020)
11.2 Global Kidney Cancer Drugs Revenue Market Share by Application (2015-2020)
11.3 Global Kidney Cancer Drugs Price by Application (2015-2020)
12 Market Forecast
12.1 Global Kidney Cancer Drugs Sales, Revenue and Growth Rate (2021-2025)
12.2 Kidney Cancer Drugs Market Forecast by Regions (2021-2025)
12.2.1 North America Kidney Cancer Drugs Market Forecast (2021-2025)
12.2.2 Europe Kidney Cancer Drugs Market Forecast (2021-2025)
12.2.3 Asia-Pacific Kidney Cancer Drugs Market Forecast (2021-2025)
12.2.4 South America Kidney Cancer Drugs Market Forecast (2021-2025)
12.2.5 Middle East & Africa Kidney Cancer Drugs Market Forecast (2021-2025)
12.3 Kidney Cancer Drugs Market Forecast by Type (2021-2025)
12.3.1 Global Kidney Cancer Drugs Sales Forecast by Type (2021-2025)
12.3.2 Global Kidney Cancer Drugs Market Share Forecast by Type (2021-2025)
12.4 Kidney Cancer Drugs Market Forecast by Application (2021-2025)
12.4.1 Global Kidney Cancer Drugs Sales Forecast by Application (2021-2025)
12.4.2 Global Kidney Cancer Drugs Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Kidney Cancer Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Kidney Cancer Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Kidney Cancer Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Bayer Basic Information, Manufacturing Base and Competitors
Table 8. Bayer Kidney Cancer Drugs Major Business
Table 9. Bayer Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 10. Bayer SWOT Analysis
Table 11. Bayer Kidney Cancer Drugs Product and Services
Table 12. Bayer Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Amgen Basic Information, Manufacturing Base and Competitors
Table 14. Amgen Kidney Cancer Drugs Major Business
Table 15. Amgen Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 16. Amgen SWOT Analysis
Table 17. Amgen Kidney Cancer Drugs Product and Services
Table 18. Amgen Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Novartis Basic Information, Manufacturing Base and Competitors
Table 20. Novartis Kidney Cancer Drugs Major Business
Table 21. Novartis Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 22. Novartis SWOT Analysis
Table 23. Novartis Kidney Cancer Drugs Product and Services
Table 24. Novartis Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Roche Basic Information, Manufacturing Base and Competitors
Table 26. Roche Kidney Cancer Drugs Major Business
Table 27. Roche Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 28. Roche SWOT Analysis
Table 29. Roche Kidney Cancer Drugs Product and Services
Table 30. Roche Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Active Biotech Basic Information, Manufacturing Base and Competitors
Table 32. Active Biotech Kidney Cancer Drugs Major Business
Table 33. Active Biotech Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 34. Active Biotech SWOT Analysis
Table 35. Active Biotech Kidney Cancer Drugs Product and Services
Table 36. Active Biotech Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 38. GlaxoSmithKline Kidney Cancer Drugs Major Business
Table 39. GlaxoSmithKline Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 40. GlaxoSmithKline SWOT Analysis
Table 41. GlaxoSmithKline Kidney Cancer Drugs Product and Services
Table 42. GlaxoSmithKline Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. ArQule Basic Information, Manufacturing Base and Competitors
Table 44. ArQule Kidney Cancer Drugs Major Business
Table 45. ArQule Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 46. ArQule SWOT Analysis
Table 47. ArQule Kidney Cancer Drugs Product and Services
Table 48. ArQule Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
Table 50. Abbott Laboratories Kidney Cancer Drugs Major Business
Table 51. Abbott Laboratories Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 52. Abbott Laboratories SWOT Analysis
Table 53. Abbott Laboratories Kidney Cancer Drugs Product and Services
Table 54. Abbott Laboratories Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Pfizer Basic Information, Manufacturing Base and Competitors
Table 56. Pfizer Kidney Cancer Drugs Major Business
Table 57. Pfizer Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 58. Pfizer SWOT Analysis
Table 59. Pfizer Kidney Cancer Drugs Product and Services
Table 60. Pfizer Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. Argos Therapeutics Basic Information, Manufacturing Base and Competitors
Table 62. Argos Therapeutics Kidney Cancer Drugs Major Business
Table 63. Argos Therapeutics Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 64. Argos Therapeutics SWOT Analysis
Table 65. Argos Therapeutics Kidney Cancer Drugs Product and Services
Table 66. Argos Therapeutics Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Exelixis Basic Information, Manufacturing Base and Competitors
Table 68. Exelixis Kidney Cancer Drugs Major Business
Table 69. Exelixis Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 70. Exelixis SWOT Analysis
Table 71. Exelixis Kidney Cancer Drugs Product and Services
Table 72. Exelixis Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 73. Immunicum Basic Information, Manufacturing Base and Competitors
Table 74. Immunicum Kidney Cancer Drugs Major Business
Table 75. Immunicum Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 76. Immunicum SWOT Analysis
Table 77. Immunicum Kidney Cancer Drugs Product and Services
Table 78. Immunicum Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 79. AVEO Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 80. AVEO Pharmaceuticals Kidney Cancer Drugs Major Business
Table 81. AVEO Pharmaceuticals Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 82. AVEO Pharmaceuticals SWOT Analysis
Table 83. AVEO Pharmaceuticals Kidney Cancer Drugs Product and Services
Table 84. AVEO Pharmaceuticals Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 85. Onyx Therapeutics Basic Information, Manufacturing Base and Competitors
Table 86. Onyx Therapeutics Kidney Cancer Drugs Major Business
Table 87. Onyx Therapeutics Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 88. Onyx Therapeutics SWOT Analysis
Table 89. Onyx Therapeutics Kidney Cancer Drugs Product and Services
Table 90. Onyx Therapeutics Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 91. Genentech Basic Information, Manufacturing Base and Competitors
Table 92. Genentech Kidney Cancer Drugs Major Business
Table 93. Genentech Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 94. Genentech SWOT Analysis
Table 95. Genentech Kidney Cancer Drugs Product and Services
Table 96. Genentech Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 97. Cerulean Pharma Basic Information, Manufacturing Base and Competitors
Table 98. Cerulean Pharma Kidney Cancer Drugs Major Business
Table 99. Cerulean Pharma Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 100. Cerulean Pharma SWOT Analysis
Table 101. Cerulean Pharma Kidney Cancer Drugs Product and Services
Table 102. Cerulean Pharma Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 103. Bionomics Basic Information, Manufacturing Base and Competitors
Table 104. Bionomics Kidney Cancer Drugs Major Business
Table 105. Bionomics Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 106. Bionomics SWOT Analysis
Table 107. Bionomics Kidney Cancer Drugs Product and Services
Table 108. Bionomics Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 109. Ono Pharmaceutical Kidney Cancer Drugs Type and Application
Table 110. Ono Pharmaceutical Kidney Cancer Drugs Major Business
Table 111. Ono Pharmaceutical Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 112. Ono Pharmaceutical SWOT Analysis
Table 113. Ono Pharmaceutical Kidney Cancer Drugs Product and Services
Table 114. Ono Pharmaceutical Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 115. immatics biotechnologies Basic Information, Manufacturing Base and Competitors
Table 116. immatics biotechnologies Kidney Cancer Drugs Major Business
Table 117. immatics biotechnologies Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 118. immatics biotechnologies SWOT Analysis
Table 119. immatics biotechnologies Kidney Cancer Drugs Product and Services
Table 120. immatics biotechnologies Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 121. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 122. Bristol-Myers Squibb Kidney Cancer Drugs Major Business
Table 123. Bristol-Myers Squibb Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 124. Bristol-Myers Squibb SWOT Analysis
Table 125. Bristol-Myers Squibb Kidney Cancer Drugs Product and Services
Table 126. Bristol-Myers Squibb Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 127. Oxford BioMedica Basic Information, Manufacturing Base and Competitors
Table 128. Oxford BioMedica Kidney Cancer Drugs Major Business
Table 129. Oxford BioMedica Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 130. Oxford BioMedica SWOT Analysis
Table 131. Oxford BioMedica Kidney Cancer Drugs Product and Services
Table 132. Oxford BioMedica Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 133. Wilex Basic Information, Manufacturing Base and Competitors
Table 134. Wilex Kidney Cancer Drugs Major Business
Table 135. Wilex Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 136. Wilex SWOT Analysis
Table 137. Wilex Kidney Cancer Drugs Product and Services
Table 138. Wilex Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 139. Tracon Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 140. Tracon Pharmaceuticals Kidney Cancer Drugs Major Business
Table 141. Tracon Pharmaceuticals Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 142. Tracon Pharmaceuticals SWOT Analysis
Table 143. Tracon Pharmaceuticals Kidney Cancer Drugs Product and Services
Table 144. Tracon Pharmaceuticals Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 145. Taiwan Liposome Basic Information, Manufacturing Base and Competitors
Table 146. Taiwan Liposome Kidney Cancer Drugs Major Business
Table 147. Taiwan Liposome Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 148. Taiwan Liposome SWOT Analysis
Table 149. Taiwan Liposome Kidney Cancer Drugs Product and Services
Table 150. Taiwan Liposome Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 151. Prometheus Laboratories Basic Information, Manufacturing Base and Competitors
Table 152. Prometheus Laboratories Kidney Cancer Drugs Major Business
Table 153. Prometheus Laboratories Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 154. Prometheus Laboratories SWOT Analysis
Table 155. Prometheus Laboratories Kidney Cancer Drugs Product and Services
Table 156. Prometheus Laboratories Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 157. Seattle Genetics Basic Information, Manufacturing Base and Competitors
Table 158. Seattle Genetics Kidney Cancer Drugs Major Business
Table 159. Seattle Genetics Kidney Cancer Drugs Total Revenue (USD Million) (2017-2018)
Table 160. Seattle Genetics SWOT Analysis
Table 161. Seattle Genetics Kidney Cancer Drugs Product and Services
Table 162. Seattle Genetics Kidney Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 163. Global Kidney Cancer Drugs Sales by Manufacturer (2018-2019) (K Units)
Table 164. Global Kidney Cancer Drugs Revenue by Manufacturer (2018-2019) (USD Million)
Table 165. Global Kidney Cancer Drugs Sales by Regions (2015-2020) (K Units)
Table 166. Global Kidney Cancer Drugs Sales Market Share by Regions (2015-2020)
Table 167. Global Kidney Cancer Drugs Revenue by Regions (2015-2020) (USD Million)
Table 168. North America Kidney Cancer Drugs Sales by Countries (2015-2020) (K Units)
Table 169. North America Kidney Cancer Drugs Sales Market Share by Countries (2015-2020)
Table 170. North America Kidney Cancer Drugs Revenue by Countries (2015-2020) (USD Million)
Table 171. North America Kidney Cancer Drugs Revenue Market Share by Countries (2015-2020)
Table 172. Europe Kidney Cancer Drugs Sales by Countries (2015-2020) (K Units)
Table 173. Europe Kidney Cancer Drugs Sales Market Share by Countries (2015-2020)
Table 174. Europe Kidney Cancer Drugs Revenue by Countries (2015-2020) (USD Million)
Table 175. Asia-Pacific Kidney Cancer Drugs Sales by Regions (2015-2020) (K Units)
Table 176. Asia-Pacific Kidney Cancer Drugs Sales Market Share by Regions (2015-2020)
Table 177. Asia-Pacific Kidney Cancer Drugs Revenue by Regions (2015-2020) (USD Million)
Table 178. South America Kidney Cancer Drugs Sales by Countries (2015-2020) (K Units)
Table 179. South America Kidney Cancer Drugs Sales Market Share by Countries (2015-2020)
Table 180. South America Kidney Cancer Drugs Revenue by Countries (2015-2020) (USD Million)
Table 181. South America Kidney Cancer Drugs Revenue Market Share by Countries (2015-2020)
Table 182. Middle East & Africa Kidney Cancer Drugs Sales by Countries (2015-2020) (K Units)
Table 183. Middle East & Africa Kidney Cancer Drugs Sales Market Share by Countries (2015-2020)
Table 184. Middle East & Africa Kidney Cancer Drugs Revenue by Countries (2015-2020) (USD Million)
Table 185. Middle East & Africa Kidney Cancer Drugs Revenue Market Share by Countries (2015-2020)
Table 186. Global Kidney Cancer Drugs Sales by Type (2015-2020) (K Units)
Table 187. Global Kidney Cancer Drugs Sales Share by Type (2015-2020)
Table 188. Global Kidney Cancer Drugs Revenue by Type (2015-2020) (USD Million)
Table 189. Global Kidney Cancer Drugs Revenue Share by Type (2015-2020)
Table 190. Global Kidney Cancer Drugs Sales by Application (2015-2020) (K Units)
Table 191. Global Kidney Cancer Drugs Sales Share by Application (2015-2020)
Table 192. Global Kidney Cancer Drugs Sales Forecast by Regions (2021-2025) (K Units)
Table 193. Global Kidney Cancer Drugs Market Share Forecast by Regions (2021-2025)
Table 194. Global Kidney Cancer Drugs Sales Forecast by Type (2021-2025) (K Units)
Table 195. Global Kidney Cancer Drugs Market Share Forecast by Type (2021-2025)
Table 196. Global Kidney Cancer Drugs Sales Forecast by Application (2021-2025)
Table 197. Global Kidney Cancer Drugs Market Share Forecast by Application (2021-2025)
Table 198. Direct Channel Pros & Cons
Table 199. Indirect Channel Pros & Cons
Table 200. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Kidney Cancer Drugs Picture
Figure 2. Global Sales Market Share of Kidney Cancer Drugs by Type in 2019
Figure 3. Angiogenesis Inhibitors Picture
Figure 4. mTOR Inhibitors Picture
Figure 5. Monoclonal Antibodies Picture
Figure 6. Cytokine Immunotherapy (IL-2) Picture
Figure 7. Kidney Cancer Drugs Sales Market Share by Application in 2018
Figure 8. Renal cell carcinoma (RCC) Picture
Figure 9. Transitional cell carcinoma (TCC) Picture
Figure 10. Global Kidney Cancer Drugs Market Status and Outlook (2015-2025) (USD Million)
Figure 11. United States Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Canada Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Mexico Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Germany Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 15. France Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 16. UK Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Russia Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Italy Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 19. China Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Japan Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Korea Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 22. India Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Southeast Asia Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Australia Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 25. Brazil Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Egypt Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Saudi Arabia Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 28. South Africa Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Turkey Kidney Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Global Kidney Cancer Drugs Sales Market Share by Manufacturer in 2019
Figure 31. Global Kidney Cancer Drugs Revenue Market Share by Manufacturer in 2019
Figure 32. Top 3 Kidney Cancer Drugs Manufacturer (Revenue) Market Share in 2019
Figure 33. Top 6 Kidney Cancer Drugs Manufacturer (Revenue) Market Share in 2019
Figure 34. Key Manufacturer Market Share Trend
Figure 35. Global Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 36. Global Kidney Cancer Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 37. Global Kidney Cancer Drugs Revenue Market Share by Regions (2015-2020)
Figure 38. Global Kidney Cancer Drugs Revenue Market Share by Regions in 2018
Figure 39. North America Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
Figure 40. Europe Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
Figure 42. South America Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
Figure 43. Middle East & Africa Kidney Cancer Drugs Sales and Growth Rate (2015-2020)
Figure 44. North America Kidney Cancer Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 45. North America Kidney Cancer Drugs Sales Market Share by Countries (2015-2020)
Figure 46. North America Kidney Cancer Drugs Sales Market Share by Countries in 2018
Figure 47. North America Kidney Cancer Drugs Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 48. North America Kidney Cancer Drugs Revenue Market Share by Countries in 2018
Figure 49. United States Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 50. Canada Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 51. Mexico Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 52. Europe Kidney Cancer Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 53. Europe Kidney Cancer Drugs Revenue Market Share by Countries (2015-2020)
Figure 54. Europe Kidney Cancer Drugs Revenue Market Share by Countries in 2019
Figure 55. Germany Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 56. UK Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 57. France Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 58. Russia Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 59. Italy Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 60. Asia-Pacific Kidney Cancer Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 61. Asia-Pacific Kidney Cancer Drugs Sales Market Share by Regions 2019
Figure 62. Asia-Pacific Kidney Cancer Drugs Revenue Market Share by Regions 2019
Figure 63. China Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 64. Japan Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 65. Korea Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 66. India Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 67. Southeast Asia Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 68. South America Kidney Cancer Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 69. South America Kidney Cancer Drugs Sales Market Share by Countries in 2019
Figure 70. South America Kidney Cancer Drugs Revenue Market Share by Countries in 2019
Figure 71. Brazil Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 72. Argentina Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 73. Middle East and Africa Kidney Cancer Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 74. Middle East and Africa Kidney Cancer Drugs Sales Market Share by Countries in 2019
Figure 75. Middle East and Africa Kidney Cancer Drugs Revenue Market Share by Countries (2015-2020)
Figure 76. Middle East and Africa Kidney Cancer Drugs Revenue Market Share by Countries in 2019
Figure 77. Saudi Arabia Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 78. Egypt Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 79. Turkey Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 80. South Africa Kidney Cancer Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 81. Global Kidney Cancer Drugs Sales and Growth Rate (2021-2025) (K Units)
Figure 82. Global Kidney Cancer Drugs Revenue and Growth Rate (2021-2025) (USD Million)
Figure 83. North America Sales Kidney Cancer Drugs Market Forecast (2021-2025) (K Units)
Figure 84. Europe Sales Kidney Cancer Drugs Market Forecast (2021-2025) (K Units)
Figure 85. Asia-Pacific Sales Kidney Cancer Drugs Market Forecast (2021-2025) (K Units)
Figure 86. South America Sales Kidney Cancer Drugs Market Forecast (2021-2025) (K Units)
Figure 87. Middle East & Africa Sales Kidney Cancer Drugs Market Forecast (2021-2025) (K Units)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel
卵巣がん治療薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Ovarian Cancer Treatment Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Ovarian Cancer…- 乳がん治療薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Breast Cancer Therapeutics Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Breast Cance…
- 子宮頸がん治療薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Cervical Cancer Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 2.2% in the forecast period of 2020 to 2025 and will expected to reach USD 14770 million by 2025, from USD 13550 million in 2019. The Cervical Cancer …
- CD抗原がん治療の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global CD Antigen Cancer Therapy market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The CD Antigen Cancer T…
- がんCDK阻害剤の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Cancer CDK Inhibitors market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Cancer CDK Inhibitors m…